If you are in your late 30s, 40s or early 50s and your clothes are fitting differently, particularly around the waist, you are not imagining it. The diets, calorie deficits and workouts that used to work now seem to do nothing at all.
It is easy to put this down to slipping discipline. The medical evidence says otherwise. Weight gain in midlife, and the way it settles around the middle during perimenopause and menopause, is driven by real biological changes [1, 2].
Understanding what has changed is the first step to working with your body rather than against it.
During the menopausal transition, your hormones do not wind down gradually. They rise and fall unpredictably from one month to the next. Those swings set off changes in how your body uses energy and where it stores fat [1, 2].
PERIMENOPAUSE HORMONAL SHIFT
│
┌───────────────────────┼───────────────────────┐
▼ ▼ ▼
Falling Oestrogen Insulin Resistance Sarcopenia (Muscle Loss)
│ │ │
Visceral Fat Shift Excess Fat Storage Lower Metabolic Rate
(Abdominal Belly Fat) & Carbohydrate Cravings (Fewer Calories Burned)
Oestrogen is what keeps fat sitting on your hips and thighs. As it falls in perimenopause, fat starts settling deeper in the abdomen instead, wrapped around your organs. Doctors call this visceral fat [1, 2].
The 18-year Study of Women's Health Across the Nation followed this closely. Fat accumulation doubles and muscle mass drops in a window that starts about two years before the last period and continues for two years after. The timing tracks the loss of ovarian hormones, not simply getting older [1].
Falling oestrogen makes your cells less responsive to insulin, and the pancreas releases less of it [2]. With shifts in other hormones alongside, glucose lingers in the bloodstream for longer, and more of it ends up stored as fat [2].
From around 35, women start losing muscle year on year, at roughly 1 to 1.5% a year after menopause [2, 4]. Muscle burns calories even when you are doing nothing, so less of it means a lower resting metabolic rate. Eat exactly what you always ate, and the weight creeps on anyway [2, 5].
When managing weight in midlife, relying solely on a bathroom scale or standard Body Mass Index (BMI) can be misleading [1, 6].
THE BATHROOM SCALE ILLUSION
Traditional Scale DEXA Body Scan
┌──────────────────────┐ ┌──────────────────────┐
│ Total Weight: 65kg │ │ Subcutaneous Fat │
│ (Shows No Change) │ │ Visceral Fat (+2kg) │
└──────────────────────┘ │ Lean Muscle (-2kg) │
└──────────────────────┘
During perimenopause, it is common to lose about two kilograms of muscle and gain about two kilograms of visceral fat at the same time [1]. The number on your bathroom scale does not move, so nothing looks wrong. Underneath, your body has changed considerably, and so has your metabolic health [1, 6].
A DEXA scan is the clinical gold standard for measuring what your body is actually made of [1, 6]. Where a scale gives you one number, a DEXA scan separates it out:
Visceral fat is worth knowing about because it does not sit there quietly. It releases substances that cause low-grade inflammation, which raises your risk of heart disease, pushes cholesterol in the wrong direction, and makes blood sugar harder to control [1, 2, 7].
When addressing midlife weight gain, comprehensive medical evaluation helps rule out overlapping conditions and identify metabolic targets [8].
Our doctors treat weight as a medical question, not a willpower one. We look for what is actually driving the changes you are seeing, then build a plan around what we find.
What's included
Blood tests
A panel covering the hormonal and metabolic factors described above.
DEXA body composition scan
This measures your muscle, your visceral fat and your bone density, so you can see what the scale cannot. It matters most in midlife, when muscle and fat can shift substantially while your weight stays the same. It also gives your doctor a baseline to measure progress against, rather than relying on the number on the scale.
Consultation with a doctor, in clinic or by video
A conversation about your symptoms, medical history, medications, daily life and what you want to achieve. Your doctor will also look at whether perimenopause or menopause is playing a part, and whether MHT is worth considering.
Personalised treatment
Your doctor goes through your results with you and sets out what to do next. That might be changes to how you eat and move, support with menopause symptoms, or prescription weight-management medication such as a GLP-1 where it is clinically appropriate.
Effective midlife weight management requires a doctor-led, multi-pronged approach that addresses hormone stability, metabolic health, and muscle preservation [2, 8].
DOCTOR-LED MIDLIFE WEIGHT TOOLKIT
│
┌─────────────────────────────┼─────────────────────────────┐
▼ ▼ ▼
Doctor-Led Interventions Menopause Hormone Therapy Preserving Muscle Mass
(e.g. GLP-1 Medications) (MHT / HRT) (Protein & Resistance)
Addresses Insulin Restores Sleep & Joint 1.2–1.5 g/kg Protein +
Resistance & Appetite Comfort to Enable Movement Strength Training
GLP-1 medications such as semaglutide and tirzepatide copy a hormone your gut releases after eating. They improve how your body responds to insulin, steady your blood sugar, slow how quickly your stomach empties, and turn down the appetite signals in your brain [12, 13].
They work particularly well in women. Large trials show substantial weight loss, and analyses suggest women often lose more, relative to their starting weight, than men do [14, 15].
Protecting your muscle matters. Losing weight quickly means losing muscle alongside fat, and unmanaged, muscle can account for 20 to 38% of everything lost. This is why guidelines are clear that GLP-1 treatment should go alongside strength training and enough protein [16, 17, 18, 19].
MHT is not a weight-loss treatment, and international medical societies do not recommend prescribing it for weight alone [8, 11].
That said, trials show women on MHT accumulate less belly fat and see smaller increases in waist measurement than women who are not [1, 6, 9].
The bigger contribution is indirect. Treating the symptoms that get in the way (broken sleep, aching joints, low mood) gives you back the energy and physical comfort that healthy habits actually require [2, 8].
Eat more protein than you think you need. Studies in postmenopausal women suggest 1.2 to 1.5 grams per kilogram of body weight a day helps hold on to muscle and reduce belly fat while eating less overall [21, 22]. Around 35 grams of good-quality protein per meal appears to be the amount that best triggers muscle repair [22].
Lift progressively heavier things. Strength training protects your muscle, improves how your body handles insulin, and defends your bone density while you lose weight [19, 20].
Yes. As oestrogen falls, your body changes where it stores fat, moving it from your hips and thighs to deeper inside your abdomen [1, 2]. You may find your waistband getting tighter while the scale says nothing has changed [1, 6].
Yes, with a doctor overseeing it [12, 16]. Your doctor will go through your health history first, and will recommend strength training and a protein target alongside the medication to protect your muscle while you lose weight [16, 19].
No. The evidence shows MHT does not cause weight gain [1, 6]. Women taking it actually accumulate less belly fat through the menopause transition than women who are not [1, 6, 9]. Some women do feel bloated or hold water in the first few weeks, which settles on its own. That is not fat.
References
El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532. doi:10.1161/CIR.0000000000000912.
Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T. Menopause: A Cardiometabolic Transition. The Lancet Diabetes & Endocrinology. 2022;10(6):442-456. doi:10.1016/S2213-8587(22)00076-6.
Vieira-Potter VJ, Mishra G, Townsend KL. Health of Adipose Tissue: Oestrogen Matters. Nature Reviews Endocrinology. 2025;21(3):145-158. doi:10.1038/s41574-025-01180-2.
Zhang W, Wu Q, Chen Q, et al. Adipose-Muscle Crosstalk During the Menopausal Transition: Mechanistic Links to Sarcopenic Obesity in Midlife Women. Frontiers in Endocrinology. 2026;17:1805067. doi:10.3389/fendo.2026.1805067.
Farhana F, Sultana MA, Hia RA, Hegde V. Postmenopausal Sarcopenia and Alzheimer's Disease: The Interplay of Mitochondria, Insulin Resistance, and Myokines. Neuroscience and Biobehavioral Reviews. 2025;170:106501. doi:10.1016/j.neubiorev.2025.106501.
Papadakis GE, Hans D, Gonzalez Rodriguez E, et al. Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort. The Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1948-1957. doi:10.1210/jc.2017-02449.
Dong J, Hillman S, Dixon S, et al. Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions. BJOG: An International Journal of Obstetrics and Gynaecology. 2026;133(2):180-192. doi:10.1111/1471-0528.70214.
Kapoor E, Collazo-Clavell ML, Faubion SS. Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management. Mayo Clinic Proceedings. 2017;92(10):1552-1558. doi:10.1016/j.mayocp.2017.08.004.
Hetemäki N, Robciuc A, Vihma V, et al. Adipose Tissue Sex Steroids in Postmenopausal Women With and Without Menopausal Hormone Therapy. The Journal of Clinical Endocrinology and Metabolism. 2025;110(2):511-522. doi:10.1210/clinem/dgae458.
Van Pelt RE, Gozansky WS, Wolfe P, et al. Estrogen or Raloxifene During Postmenopausal Weight Loss: Adiposity and Cardiometabolic Outcomes. Obesity (Silver Spring). 2014;22(4):1024-1031. doi:10.1002/oby.20653.
Kunicki M, Katulska Z, Wolert W, Kunicka A. Obesity Treatment for Postmenopausal Women: Established Therapies and Emerging Approaches - A Narrative Review. Maturitas. 2026;211:109025. doi:10.1016/j.maturitas.2026.109025.
Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials. Annals of Internal Medicine. 2025;178(2):199-217. doi:10.7326/ANNALS-24-01590.
Vienghirun J, Sawangjit R, Suttiruksa S, et al. GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs. Diabetes, Obesity & Metabolism. 2026;28(6):5043-5057. doi:10.1111/dom.70698.
Ruder K. At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide. JAMA. 2024;331(1):9-11. doi:10.1001/jama.2023.23123.
Alexander GC, Xiao X, Dilek S, et al. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults. JAMA Internal Medicine. 2026;186(3):284-295. doi:10.1001/jamainternmed.2025.8222.
Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.
Lieberman DE, Aslan DH, Heymsfield SB. The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era. JAMA. 2026;335(4):312-320. doi:10.1001/jama.2026.5537.
Sawicka-Gutaj N, Gruszczyński D, Nijakowski K, et al. GLP-1 Agonists and Changes in Body Mass and Composition in Adults With Overweight or Obesity With or Without Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. International Journal of Obesity. 2026;50(2):410-422. doi:10.1038/s41366-026-02088-1.
Locatelli JC, Costa JG, Haynes A, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. doi:10.2337/dci23-0100.
Neeland IJ, Linge J, Birkenfeld AL. Changes in Lean Body Mass With Glucagon-Like Peptide-1-Based Therapies and Mitigation Strategies. Diabetes, Obesity & Metabolism. 2024;26(Suppl 4):16-27. doi:10.1111/dom.15728.
Ioannidou P, Dóró Z, Schalla J, et al. Analysis of Combinatory Effects of Free Weight Resistance Training and a High-Protein Diet on Body Composition and Strength Capacity in Postmenopausal Women: A 12-Week Randomized Controlled Trial. The Journal of Nutrition, Health & Aging. 2024;28(10):100349. doi:10.1016/j.jnha.2024.100349.
Larsen MS, Witard OC, Holm L, et al. Dose-Response of Myofibrillar Protein Synthesis to Ingested Whey Protein During Energy Restriction in Overweight Postmenopausal Women: A Randomized, Controlled Trial. The Journal of Nutrition. 2023;153(11):3173-3184. doi:10.1016/j.tjnut.2023.08.011.
Li J, Jiang L, Saquib N, et al. Estimating the Effect of Hypothetical Dietary Protein Interventions on Changes in Body Composition of Postmenopausal Women Over 3 Years Using Data From the Women's Health Initiative (WHI) Study: An Emulated Target Trial. International Journal of Obesity. 2026;50(3):609-617. doi:10.1038/s41366-025-01978-0.
Over 70% of women in Singapore experience menopause m shifts, yet most go untreated. Here is your complete guide to KKH guidelines, MHT choices, MediSave, and getting care that actually connects the dots.
Decreasing oestrogen during menopause can cause rapid changes in skin texture and hydration. We break down the science behind oestrogen depletion, why off-label vaginal creams may cause irritation, and explore options like estriol cream.
A guide to how menopause hormone therapy (MHT / HRT) works, the different options available in Singapore, what they cost, and whether MHT may be suitable for you.
%20(680%20x%20250%20px)%20(1).svg)
